Scientists discover rare genetic condition that attacks kids’ immune systems
Global Hemophilia Treatment Market Set For Significant Expansion, Projected To Reach USD 18.7 Billion By 2034
The global hemophilia treatment market is poised for remarkable growth, with estimates projecting an increase from USD 12.1 billion in 2024 to an impressive USD 18.7 billion by 2034. This substantial expansion reflects a compound annual growth rate (CAGR) of 4.4% over the next decade, driven by dynamic advancements in the sector and a growing understanding of hemophilia management.
Hemophilia is a life-threatening disorder characterized by a deficiency of clotting proteins in the blood, leading to excessive and uncontrollable bleeding. Preventative treatments, such as regular injections of clotting factors, play a crucial role in mitigating the frequency and severity of bleeding episodes, particularly for patients with hemophilia A. These treatments not only enhance the body's ability to form clots but also significantly improve the quality of life for those affected by this condition.
The current treatment landscape includes component replacements derived from human plasma and recombinant products, which work by increasing clotting factors in the body. Healthcare providers typically prescribe either prophylactic or episodic treatments tailored to the patient's needs. Prophylactic treatments aim to prevent bleeding episodes, while episodic treatments are administered in response to bleeding events. The ability for patients to perform infusions at home has revolutionized hemophilia care, enabling more effective and efficient management of their condition.
One of the most promising developments in hemophilia treatment is gene therapy, an area of ongoing research and innovation. Recent FDA approvals for gene therapy treatments for both hemophilia A and hemophilia B mark significant milestones in the field. These genetic therapies have the potential to provide long-term solutions by addressing the underlying genetic causes of hemophilia and supplying the missing clotting factors for extended periods.
As the global hemophilia treatment market continues to expand, the focus remains on developing more effective and accessible treatments to enhance the lives of patients worldwide. With ongoing advancements in gene therapy and other innovative approaches, the future of hemophilia treatment holds great promise.
"Advancements in treatment and revolutionary approaches to gene therapies have driven hemophilia treatment demand to unprecedented heights. Developments in diagnostics and ongoing developments in hemophilia treatments are expected to expand the market for hemophilia treatments in years ahead." – Says an analyst at FMI.
Key Takeaways from the Hemophilia Treatment Market:
Increased Market Insight Demand: Get Thorough Analysis and Trends in Our Complete Report!
Competitive Landscape:
Hemophilia treatment companies are actively investing in research and development in order to introduce novel therapies to the global market. As part of their growth strategy, these companies are implementing acquisitions, mergers, product developments and approvals, collaborative ventures, etc.
Recent Development:
Key Players of the Hemophilia Treatment Industry:
Hemophilia Treatment Market Segmentation
By Drug Class:
In terms of drug class, the industry is divided into clotting factors (recombinant factor concentrates, plasma-derived factors concentrate), monoclonal antibodies, antidiuretic and antihemorrhagic drugs, aminocaproic acid, antifibrinolytic agents, and gene therapy.
By Indication:
In terms of indication, the industry is segregated into a hemophilia A, hemophilia B, and Von Willebrand disease.
By Distribution Channel:
In terms of distribution channel, the industry is segmented into hospitals, specialized clinics, retail pharmacies, and mail order pharmacies.
By Region:
Key countries of North America, Latin America, Western Europe, Eastern Europe, South Asia, East Asia, Middle East, and Africa have been covered in the report.
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.Christiana Corporate, 200 Continental Drive,Suite 401, Newark, Delaware – 19713, USAT: +1-845-579-5705For Sales Enquiries: sales@futuremarketinsights.ComWebsite: https://www.Futuremarketinsights.ComLinkedInTwitterBlogsYouTube
World Hemophilia Day 2009: "Together, We Care"
"Together, We Care" stands as the slogan for World Hemophilia Day 2009 celebrated on 17th April. The theme embodies a spirit of collaborated and comprehensive care globally to give physical, emotional and psychological treatment for hemophilia patients. 'Treatment for All' could be achieved mainly through correct diagnosis, management and comprehensive care by a group of specialists.
Hemophilia is a genetically inherited, rare bleeding disorder, wherein the blood does not clot normally. Hemophilia could run into generations since it is genetically inherited. Mostly men are affected by hemophilia. Women are just carriers, who take it to future generations. They carry it on one of the two x chromosomes and pass it to their sons through the chromosome. Hemophilia is not carried on the Y chromosome which males receive from their fathers. Hemophilia was so common among Europe's nobles in medieval times that it used to be called the "malaise des rois" or disease of kings.People with hemophilia would bleed longer than others when an injury happens because they have less or none of a protein clotting factor.
Hemophilia A and Hemophilia B are the two main types of hemophilia. Normally there are 13 different blood components called factors that help with the clotting mechanism in the body. Hemophilia A results from low levels or none of clotting factor VIII, while Hemophilia B is due to low levels or none of clotting factor IX. Depending on the amount of clotting factor present in the blood, hemophilia could be mild, moderate or severe.
Like any other disease, hemophilia also has its signs and symptoms. Hemophilia symptoms may present for the first time during any scheduled surgery.
• Excessive external bleeding that may first present after scheduled dental surgery, injury or any other surgery.• Internal bleeding in the joints such as the elbows, knee or other joints.• Bleeding could also occur in the brain. This could be fatal if immediate care is not given.
The bleeding from hemophilia can have fatal consequences hence treating it is very important. The disease cannot be cured, but it can be treated with effective management and proper knowledge of the disease. "It is very good to take advantage of all the different types of therapy you can" says Antonio, a hemophilia patient who lives in Argentina.
Treatments are as follows:
Replacement Therapy: This is an important method to treat hemophilia. It is done by replacing the missing or limited clotting factor. For Hemophilia A, clotting factor VIII is given. Hemophilia B needs clotting factor IX. The treatment involves preventive or prophylactic therapy, which is given in a regular basis. Demand therapy is given only when there is a need to stop bleeding.
Home treatment with replacement therapy: It is done by infusions into the veins. Home treatment helps in treating the patient faster, thereby reducing complications. Doctor visits are reduced and also the treatment is cost effective.
Other Treatments
Desmopressin: A man-made factor Desmopressin (DDAVP) treats mild Hemophilia A. It stimulates the factor VIII and von Willebrand factor to increase the protein levels in the blood. Desmopressin is given by an injection or as nasal spray.
Antifibrinolytic medicines: It is a pill that keeps clots from breaking down. These pills are given before dental work, mouth or nose bleeding treatment and for mild intestinal bleeding.
Gene Therapy: Scientists are doing their best to correct the defective genes responsible for hemophilia. The therapy is still on trial basis.
Hemophilia care: Hemophilia treatment does not stop with just medicines, but goes beyond that. Hemophilia treatment centers give treatment, education and assistance for hemophilia patients and their families. These centers have a team of nurses, pediatricians, hematologists, social workers, physical therapists and dentists.
World Hemophilia Day gives us the chance to explore the challenges facing this complex disease. "Our challenge is to ensure that all people with bleeding disorders, no matter where they live, receive proper treatment and care," says Mark Skinner, World Federation of Hemophilia president. So, let us strive for a collaborative and comprehensive hemophilia treatment. Together, we can do it!
Source-MedindiaAruna/L
Kenya: East African Nations Hold Forum To Tackle Blood Disorders And Enhance Patient Care
Nairobi — Countries from East Africa convened at the East Africa Blood Disorders Leadership Forum to address the future of bleeding and blood disorders (BBDs) affecting citizens, such as sickle cell anemia, hemophilia, and von Willebrand disease.
The forum gathered regional leaders, patient organizations, government officials, and patients to strengthen advocacy and advance treatment and care for those impacted by these disorders.
Dr. Gladwell Gathecha, Head of the Division of Non-Communicable Diseases (NCD) in Kenya's Ministry of Health, outlined strategies from Kenya's NCD strategic plan (2021-2025) to standardize quality care for hemophilia and sickle cell patients. "We've developed guidelines for healthcare workers from Kisumu to Mombasa to ensure consistent, high-quality services for these patients," Dr. Gathecha noted. Another key strategy is the establishment of the Hematological Disease Technical Working Group, which coordinates with the Ministry of Health on blood disorder management.
Dr. Gathecha also highlighted initiatives through the Social Health Insurance Act (SHA) to cover diagnostic testing for sickle cell disease. The Emergency Chronic and Critical Illness Fund, she explained, provides additional support for people living with chronic blood disorders. "These are lifelong diseases, sometimes hereditary, and can severely impact quality of life," she added.
Dr. Kibet Shikuku, Chair of the Kenya Hemophilia Association, emphasized the importance of government involvement in patient care. "Patients don't belong to doctors--they belong to the government. Greater government involvement will fast-track solutions," he said, advocating for resource mobilization to enhance treatment access across East Africa. Dr. Shikuku cited a 75% treatment gap for blood disorder patients in the region, stressing the need for shared resources, research, and expertise to improve care.
Participants urged governments to allocate funds for locating and treating affected citizens, ensuring that BBD patients across the region receive the support they need.
Comments
Post a Comment